Cardiopulmonary Toxicity of Thoracic Radiotherapy
Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Jun 4, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the effects of thoracic radiotherapy, a treatment commonly used for patients with oesophageal cancer and non-small cell lung cancer (NSCLC). Researchers want to understand how this treatment might affect the heart and lungs, particularly looking at a condition called pulmonary hypertension (PH), which can occur after radiation therapy. They are interested in finding out if radiation treatment could lead to serious heart and lung problems that might shorten survival, even though these side effects are often overlooked.
To participate in the trial, you need to be an adult (18 years or older) with specific types of cancer, such as mid or distal oesophageal cancer or certain stages of lung cancer, and you should be scheduled to receive radiotherapy with the aim of curing your cancer. Participants will undergo various tests during the study, including MRI scans, to monitor any changes in their heart and lung function. Importantly, the findings could help improve treatment plans and possibly prevent severe complications in the future. If you're considering joining, make sure to discuss it with your healthcare team to see if it’s the right choice for you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with oesophageal cancer in the mid or distal oesophagus and patients with NSCLC stage IIA-III or NSCLC stage IV with limited brain metastases (treatable with surgery or stereotactic radiosurgery) or SCLC limited disease (stage I-IIIB)
- • Scheduled for external-beam radiotherapy with curative intention.
- • WHO 0-2.
- • Age \>= 18 years
- • Written informed consent.
- Exclusion Criteria:
- • No heart failure in the last 2 months
- • No pulmonary embolism in the last 2 months
- • COPD gold IV
- • BMI \>35
- • History of thoracic radiotherapy
- • Noncompliance with any of the inclusion criteria - For MRI part: Contra indications for MRI
- For MRI part:
- • • contra-indications for MRI
About University Medical Center Groningen
University Medical Center Groningen (UMCG) is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research, high-quality patient care, and extensive education in the medical field. As a prominent sponsor of clinical trials, UMCG leverages its multidisciplinary expertise and state-of-the-art facilities to advance medical knowledge and improve therapeutic outcomes. The center fosters collaboration among researchers, healthcare professionals, and industry partners, aiming to translate scientific discoveries into effective treatments that enhance patient health and well-being. With a focus on ethical standards and regulatory compliance, UMCG is dedicated to conducting clinical trials that contribute to the advancement of medicine and the betterment of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Glasgow, , United Kingdom
Leuven, , Belgium
Nijmegen,, Gelderland, Netherlands
Glasgow, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials